Carglumic acid, sold under the brand name Carbaglu among others, is used for the treatment of hyperammonaemia.Carglumic acid is a carbamoyl phosphate synthetase 1 (CPS 1) activator.The most common adverse effects include vomiting, abdominal pain, pyrexia (fever), and tonsillitis, anemia, diarrhea, ear infection, other infections, nasopharyngitis, decreased hemoglobin levels, and headache.It was approved for medical use in the United States in March 2010. Carglumic acid is an orphan drug. Medical uses
Carglumic acid is indicated for the treatment of acute hyperammonemia and chronic hyperammonemia. References
External links
"Carglumic acid". Drug Information Portal. U.S. National Library of Medicine.
It is thought that due to the co-occurrence of these two disorders they may have a common etiology.As a feature of GLHS one case study has shown GLHS to co-occur with autism spectrum disorder. Epidemiology
As of 2018 only 36 cases have been reported. History
The first case was reported by Heinrich Obersteiner in 1914. == References ==